US Patent Issued to AstraZeneca on March 24 for "Stable, aqueous formulations of antibodies that bind IL5 receptor" (Maryland Inventors)

ALEXANDRIA, Va., March 24 -- United States Patent no. 12,582,716, issued on March 24, was assigned to AstraZeneca AB (Sodertalje, Sweden).

"Stable, aqueous formulations of antibodies that bind IL5 receptor" was invented by William Leach (Gaithersburg, Md.), Rachael Lewus (Gaithersburg, Md.), James McGivney (Gaithersburg, Md.), Kelcy Newell (Gaithersburg, Md.) and Kevin Douglas Stewart (Gaithersburg, Md.).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present invention relates to stable, aqueous antibody formulations. In some embodiments, the stable, aqueous formulations comprise about 2 mg/mL to about 100 mg/mL of an anti-IL5R antibody, and about 0.002% to about 0.01% polysorbate-20. Also provided are met...